Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-08-16
2011-08-16
Goddard, Laura B (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007100
Reexamination Certificate
active
07998695
ABSTRACT:
Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. In particular, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer.
REFERENCES:
patent: 7001999 (2006-02-01), Martelange et al.
patent: 2004/0076955 (2004-04-01), Mack et al.
patent: 2004/0241726 (2004-12-01), Liew
patent: 2004/0253232 (2004-12-01), Jakobovits et al.
patent: 2010/0184088 (2010-07-01), Nakatsuru
patent: WO 01/22864 (2001-04-01), None
patent: WO 01/53312 (2001-07-01), None
patent: WO 01/53535 (2001-07-01), None
patent: WO 02/31111 (2002-04-01), None
patent: WO 03/083074 (2003-10-01), None
patent: WO 2004/031413 (2004-04-01), None
patent: WO 2004/112589 (2004-12-01), None
patent: WO 2005/090603 (2005-09-01), None
patent: WO 2008/047473 (2008-04-01), None
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Ardelt, Peter, et al., “Gene and Antisense Therapy of Bladder Cancer,” Bladder Disease: Research Concepts and Clinical Application,Adv. Exp Med Biol., 539 (Pt A), pp. 155-183 (2003).
Fuessel, Susanne, et al., “Systematic In Vitro Evaluation of Survivin Directed Antisense Oligodeoxynucleotides In Bladder Cancer Cells,”The Journal of Urology, vol. 171, pp. 2471-2476 (Jun. 2004).
Modlich, Olga, et al., “Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder . . . ”Clinical Cancer Research, vol. 10, pp. 3410-3421 (May 15, 2004).
Nicholson, Brian E., et al., “Profiling the Evolution of Human Metastic Bladder Cancer,”Cancer Research, vol. 64, pp. 7813-7821 (Nov. 1, 2004).
Smith, Shannon D., et al., “Urine Detection of Survivin and Diagnosis of Bladder Cancer,”JAMA, vol. 285(3), pp. 324-328 (Jan. 17, 2001).
Tyagi, Anil K., et al., “Silibinin down-regulates survivin protein and mRNA expression . . . ”Biochemical and Biophysical Res Commun., vol. 312, pp. 1178-1184 (Dec. 26, 2003).
GEO Accession Viewer, “Affymetrix GeneChip Human Genome U133 Plus 2.0 Array,” Internet Article [Online], entire document, Available: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL570 (Nov. 7, 2003).
Greenbaum, D., et al., “Comparing protein abundance and mRNA expression levels on a genomic scale,”Genome Biology, vol. 4(9), pp. 117.1-117.8 (2003, Epub Aug. 29, 2003).
Greenbaum, D., et al., “Interrelating Different Types of Genomic Data, from Proteome to Secretome: 'Oming in on Function,”Genome Research, vol. 11(9), pp. 1463-1468 (Sep. 2001).
Lu, P., et al,. “siRNA-mediated antitumorigenesis for drug target validation and therapeutics,”Current Opinion in Molecular Therapeutics, vol. 5(3), pp. 225-234 (Jun. 2003).
Ota, T., et al., “Complete sequencing and characterization of 21,243 full-length human cDNAs,” Nat. Genet., vol. 36(1), pp. 40-45 (Jan. 2004); Genbank Accession No. NM—017779:2004.10.28 (XP007907000), 3 pgs.
Sanchez-Carbayo, M., “Recent advances in bladder cancer diagnostics,”Clinical Biochemistry, vol. 37(7), pp. 562-571 (Jul. 2004).
Tang, Y., et al., “FLJ20354 fis clone HEP15013,” Accession No. ABP43909:2000.10.12 (XP007907002), 2 pgs. (Oct. 12, 2000).
U.S. Appl. No. 12/377,024, which is a U.S. Nat'l Phase of PCT/JP2007/065992, filed Aug. 10, 2007, 221 pgs.
U.S. Appl. No. 12/666,253, filed Jun. 14, 2010, 72 pgs.
U.S. Appl. No. 12/673,432, which is a U.S. Nat'l Phase of PCT/JP2008/064437, filed Aug. 12, 2008, 83 pgs.
U.S. Appl. No. 12/673,434, which is a US National Stage (371) of PCT/JP2008/060837, 102 pgs.
U.S. Appl. No. 12/673,451, filed Feb. 2, 2010, 131 pgs.
U.S. Appl. No. 12/674,759, which is a US National Stage (371) of PCT/JP2008/065352, 233 pgs.
Sanchez-Carbayo, M., “Use of High-Throughput DNA Microarrays to Identify Biomarkers for Bladder Cancer,”Clinical Chemistry, vol. 49(1), pp. 23-31 (Jan. 2003).
Suzuki, T., et al., “Expression of the Catalytic Subunit Associated with Telomerase Gene in Human Urinary Bladder Cancer,”J. Urol., vol. 162(6), pp. 2217-2220 (Dec. 1999).
U.S. Appl. No. 13/001,869, which is a US National Phase of PCT/JP2009/003009 filed Jun. 30, 2009, 63 pgs.
Netaffx, “HG-U133—PLUS—2:1555826—AT,” Internet Article [Online] entire document, Available: http://www.affymetrix.com/analysis/index.affx (Jun. 22, 2006).
Katagiri Toyomasa
Nakamura Yusuke
Nakatsuru Shuichi
Goddard Laura B
Kilpatrick Townsend & Stockton LLP
Oncotherapy Science, Inc.
LandOfFree
Method of diagnosing bladder cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of diagnosing bladder cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of diagnosing bladder cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2766549